Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2030?

- [2024-08-09] FDA issued a Complete Response Letter (CRL) rejecting Lykos Therapeutics' original NDA for midomafetamine (MDMA) capsules for PTSD, requesting an additional Phase 3 study from Lykos to further evaluate MDMA's safety and efficacy . https://phillipslytle.com/fda-denies-approval-of-new-drug-application-for-mdma-and-requests-additional-study/ - [2025-09-04] FDA publicly released the CRL text, detailing 3 main concerns, 8 safety components, and 9 trial suggestions that do not affect approvability , including failure to report positive/abuse-potential adverse events. https://www.hcplive.com/view/fda-releases-crl-detailing-safety-concerns-mdma-assisted-therapy-ptsd - [2025-08 (renamed)] The company, formerly MAPS PBC and Lykos Therapeutics, was renamed Resilient Pharmaceuticals in August 2025 . - [2026-04-18] President Trump signed Executive Order 14401, "Accelerating Medical Treatments for Serious Mental Illness," directing federal agencies to expedite the research, review, and approval of psychedelic drugs , directing FDA to issue Commissioner's National Priority Vouchers to qualifying psychedelics with Breakthrough Therapy designation. https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/ - [2026-04-24] FDA Commissioner Marty Makary announced FDA had issued three priority vouchers to Compass Pathways' psilocybin, Usona Institute, and (per other reporting) Transcend Therapeutics — notably MDMA/Resilient was NOT among the three voucher recipients. https://www.foley.com/insights/publications/2026/04/psychedelics-and-the-executive-order-from-schedule-i-to-treatment-priority/ - [2026-07] FDA published its final guidance, "Psychedelic Drugs: Considerations for Clinical Investigations," finalizing a draft first issued in June 2023 . https://maps.org/2026/08/10/maps-responds-to-report-of-progress-for-mdma-assisted-therapy-for-ptsd-with-fda/ - [2026-08-09] Per Psychedelic Alpha sourcing, the resubmission comes almost exactly two years after FDA first rejected the package , with Resilient Pharmaceuticals resubmitting its MDMA NDA for PTSD "without a new phase 3 trial," instead relying on a new Phase I safety study in 32 healthy volunteers and a third-party audit of prior Phase 3 data. https://psychedelicalpha.com/news/two-years-after-rejection-resilient-quietly-refiles-mdma-for-ptsd-application/ - [2026-08-10] MAPS confirmed the resubmission in a statement but noted the new NDA is being submitted without a new Phase 3 study ; MAPS has no operational role in Resilient's program. https://maps.org/2026/08/10/maps-responds-to-report-of-progress-for-mdma-assisted-therapy-for-ptsd-with-fda/ - [2026-08-12] Psychedelic Alpha reported the resubmission has not yet been confirmed by FDA as accepted for review; a knowledgeable source noted "it's a safe bet that any data flows might include information from psychedelics studies" from a new FDA-VA data-sharing MOU, and floated a possible compromise path involving a REMS program rather than straight rejection or approval. https://psychedelicalpha.com/news/two-years-after-rejection-resilient-quietly-refiles-mdma-for-ptsd-application/ - [2026-09-14/10-05] FDA/HHS held a public hearing (Sept. 14) and comment period (through Oct. 5) on implementation of the psychedelic guidance, covering "(1) provider training and credentialing, (2) promotion of patient safety, (3) considerations..." for psychedelic therapies generally — not MDMA-specific, but relevant to eventual REMS/label design. https://themicrodose.substack.com/p/veterans-affairs-continues-to-drive - [2026-10-06] HCPLive's Q3 2026 psychiatry recap confirms "Resilient Pharmaceuticals resubmitted its MDMA-assisted therapy new drug application (NDA) for PTSD" as a key Q3 event, with no FDA acceptance/PDUFA date or decision reported yet as of early October 2026. https://www.hcplive.com/view/q3-2026-recap-psychiatry-news-updates - [As of 2026-10-07] No public confirmation that FDA has formally "accepted" the resubmitted NDA for filing/review, no PDUFA target action date has been reported, and no new Advisory Committee meeting has been scheduled; Stifel analysts speculated a possible new NDA filing "could be filed, likely sometime in the first half of next year" referring to a different (follow-on) timeline, underscoring overall uncertainty about pace. https://psychedelicstoday.com/2026/08/18/mdma-nda-resubmitted-fda-august-2026/ BOTTOM LINE: As of October 7, 2026, MDMA/midomafetamine for PTSD remains unapproved; Resilient Pharmaceuticals resubmitted its NDA around August 9, 2026 without a new Phase 3 trial, benefiting from a favorable political climate (April 2026 executive order, new FDA psychedelic guidance) but it did not receive one of FDA's three psychedelic priority vouchers, FDA has not publicly confirmed acceptance of the filing or set a PDUFA date, and no new Advisory Committee meeting or decision has been scheduled — leaving a standard (likely 10-12 month, possibly longer given prior CRL) review timeline that could plausibly conclude before January 1, 2030, but with substantial uncertainty and no confirmed near-term approval date. NOT FOUND: Confirmation of FDA formal acceptance/filing of the August 2026 resubmission (60-day filing review decision), any PDUFA/target action date for the current review cycle, any new Advisory Committee meeting date, and any statement from Resilient Pharmaceuticals itself on the resubmission (company has not issued its own public statement).

- [2024-06-04] An FDA advisory committee voted overwhelmingly against MDMA-assisted psychotherapy for PTSD, 9-2 against efficacy and 10-1 against benefits outweighing risks — a strongly negative outside-view signal, since adcomm rejections of this magnitude rarely precede approval on the same data package. Source: https://en.wikipedia.org/wiki/Lykos_Therapeutics - [2024-08-09] FDA issued a Complete Response Letter to Lykos, requesting that Lykos conduct an additional Phase 3 trial to further study the safety and efficacy of MDMA , the most demanding form of CRL outcome. Source: https://www.psychiatrist.com/news/fda-rejects-mdma-assisted-ptsd-therapy/ - [2025-09-04] The FDA publicly released the CRL, which cited unreported abuse-related adverse events, lack of data on MDMA's long-term efficacy, and selection bias due to prior MDMA use among participants — three substantive dealbreakers rather than minor CMC issues. Source: https://www.hcplive.com/view/fda-releases-crl-detailing-safety-concerns-mdma-assisted-therapy-ptsd - [2026-08-09] Resilient Pharmaceuticals (formerly Lykos/MAPS PBC) resubmitted the NDA, but the resubmission proceeded without a new phase 3 trial, with proponents arguing core efficacy and adverse event reporting remained accurate despite partial functional unblinding — i.e., the sponsor did not do the pivotal trial the CRL explicitly demanded, instead relying on an audit, a small VA dataset, and a 32-person Phase I safety study (per Psychedelic Alpha, 2026-08-12). - [2026-04-18/24] A White House executive order directed FDA to issue "National Priority Vouchers" (1-2 month reviews) to Breakthrough-Therapy psychedelics, but the first three vouchers issued went to Compass Pathways for COMP360 psilocybin, Usona for psilocybin, and Transcend Therapeutics for methylone (TSND-201) for PTSD — notably NOT to Resilient's MDMA, suggesting the agency did not yet view the MDMA PTSD package as voucher-ready. Source: https://www.medicaldaily.com/psilocybin-fda-priority-review-2026-compass-pathways-depression-ptsd-approval-475666 - [2025-11 analysis] Historical reference class: in a broad 2013-2023 dataset of NDAs, 47 of 358 submissions (13%) received at least one CRL, of which 30 (64% of CRL cases) were ultimately approved by 2025, while 36% remained unapproved or were withdrawn . Source: https://www.sciencedirect.com/science/article/pii/S1359644626001443 - [n.d., retrospective JAMA-based analysis] Separately, FDA's own retrospective found safety issues are easier to overcome on resubmission than are efficacy issues — relevant because MDMA's CRL combined both efficacy (durability, bias) and safety (unreported adverse events) deficiencies, the hardest-to-resolve combination category. Source: https://www.nature.com/articles/nrd4272 - [2011-vintage industry data, still commonly cited] An older BIO-sponsored analysis found only 1.4% of submissions made after the third round of submissions obtained approval , and even first CRL resubmissions carried a median delay of 13 months for Class 2 (major) resubmissions, ranging from 3.5 to 26 months . This is the MDMA application's second review cycle (first CRL already issued), typically a major/Class 2 category given the clinical trial deficiencies cited. Source: https://www.raps.org/resource/study-shows-impact-of-complete-response-letters-on.html - [2026-08-12] Industry reporting notes the Division of Psychiatry (the FDA unit reviewing MDMA) is described as somewhat sheltered from external political forces, and empowered as the ultimate decision-maker , despite some advocates believing approval is a "shoo-in" — suggesting expert/insider sentiment is less bullish than public political momentum implies. Source: https://psychedelicalpha.com/news/two-years-after-rejection-resilient-quietly-refiles-mdma-for-ptsd-application/ - [2026-08-12] Industry observers note that appraisal of a resubmission is often quicker than a new submission , and expect review timelines to compress versus the original ~1-year process, but no FDA decision date, acceptance confirmation, or new advisory committee has been announced as of the resubmission. NOT FOUND: No FDA public confirmation of NDA acceptance/filing date for the 2026 resubmission; no announced PDUFA goal date; no confirmation that Resilient/MDMA has received (or been denied) a National Priority Voucher; no published odds from prediction markets or professional forecasters specifically quantifying this outside-view base rate beyond the generic CRL-resubmission statistics above. BOTTOM LINE: The reference class for drugs combining a strongly negative adcomm vote (9-2/10-1) with a CRL citing both unresolved efficacy and safety deficiencies, where the sponsor resubmits without completing the specifically-requested pivotal trial, historically has below-average approval odds and often takes 1-2+ years per cycle even when approved; the one favorable countervailing factor is a now-active White House/FDA push for faster psychedelic reviews, though MDMA itself was passed over for the first round of priority vouchers given to rival PTSD/depression candidates.

YES means: The FDA issues an approval letter (standard, accelerated, REMS-conditioned, or restricted-distribution) for midomafetamine/MDMA-assisted therapy for PTSD, under the current Resilient Pharmaceuticals NDA or any future resubmission, before January 1, 2030 — a roughly 3-year, 3-month window from today. - [2026-08-09] Resilient Pharmaceuticals resubmitted its MDMA NDA for PTSD, and critically, prior FDA Commissioner Makary had publicly signaled a tractable path for this exact scenario, saying that if Resilient "submits the results of their audit for the protocol violation that was cited in the rejection... that'll be considered in due process" — i.e., agency leadership was not demanding a fresh Phase 3 trial as a precondition. https://psychedelicalpha.com/news/breaking-fda-awards-priority-review-vouchers-to-otsuka-compass-and-usona/ - [2026-07-14] A Federal Register notice confirms MDMA for PTSD retains its 2017 Breakthrough Therapy designation (granted to MAPS), which is the formal eligibility gate for Commissioner's National Priority Vouchers (CNPVs) under the April 2026 executive order — meaning MDMA remains structurally eligible for a future 1-2 month voucher review even though it didn't get one in the April 24 round. https://www.federalregister.gov/documents/2026/07/14/2026-14155/considerations-for-potential-future-therapeutic-use-of-psychedelic-drugs-public-hearing-request-for - [2026-09 reporting] A possible middle path floated by industry sources is that FDA could approve MDMA with a restricted-distribution/REMS program (akin to Spravato's model) rather than a binary reject/approve choice — and the question's rules explicitly count "Approval with restricted distribution or indication limitations" and "Approval with REMS" as triggering Yes. https://psychedelicalpha.com/news/two-years-after-rejection-resilient-quietly-refiles-mdma-for-ptsd-application/ - [2026-09-30 reporting] A branded trade name, "Rysanso," has already surfaced in industry coverage of the resubmission, indicating the sponsor and/or agency-adjacent sources are treating a commercial launch as a plausible near-term outcome, not a remote one. https://mindmedicinelaw.com/guides/mdma - [2026-10-05 (Q3 recap)] HCPLive's Q3 2026 recap confirms the resubmission occurred and frames it as an active, moving regulatory story rather than a dead one, consistent with a live review clock that could culminate in approval well before the 2030 deadline even under a standard (non-voucher) 10-12 month timeline plus likely delays. https://www.hcplive.com/view/q3-2026-recap-psychiatry-news-updates - [2026-04-24 analogous case] The CNPV mechanism is already functioning rapidly for sibling psychedelic programs — Compass Pathways' COMP360 psilocybin for treatment-resistant depression, after receiving a CNPV, is tracking toward a potential FDA approval decision as early as late 2026/early 2027 per the company's own Q2 2026 SEC filing, demonstrating the FDA under this administration is both willing and institutionally capable of approving a psychedelic-assisted therapy within roughly a year of a priority filing. https://www.sec.gov/Archives/edgar/data/0001816590/000181659026000059/q22026pressrelease.htm - [2026-04-18] The governing executive order itself, "Accelerating Medical Treatments for Serious Mental Illness," creates sustained top-down political pressure on FDA to expedite psychedelic approvals generally, a pressure that persists structurally (not a one-time event) through the remainder of the Trump term, covering nearly the entire remaining window to the 2030 deadline. - [2026-08-12 mechanism] Industry sourcing notes a new FDA-VA data-sharing MOU (tied to the executive order) could feed additional supportive real-world/VA trial data into FDA's review of Resilient's package, potentially helping address the durability and safety-characterization gaps cited in the 2024 CRL without requiring a formal new Phase 3 trial. https://psychedelicalpha.com/news/two-years-after-rejection-resilient-quietly-refiles-mdma-for-ptsd-application/ - [2026 reporting, resubmission dynamics] Observers note that resubmission appraisal is typically faster than a first-cycle review, and the 2026 resubmission benefits from the FDA's own newly finalized "Psychedelic Drugs" clinical guidance (finalized July 2026) that directly addresses the adverse-event-reporting and functional-unblinding issues flagged in the CRL, potentially narrowing the agency's remaining concerns to issues already partly resolved by Resilient's audit. - [Time-window argument] Even if this current review cycle fails (e.g., another CRL), the roughly 39-month runway remaining before January 1, 2030 would still allow for at least one, and plausibly two, further resubmission/review cycles at the historical ~13-month major-resubmission median delay cited in industry data, giving multiple distinct "bites at the apple" before the market's deadline — a luxury the original 2024-2026 CRL-to-resubmission cycle did not have. BOTTOM LINE: The clearest YES path is the currently pending Resilient resubmission (filed without a new Phase 3 trial) succeeding either via standard/priority review or a retroactively granted CNPV, aided by a sympathetic Commissioner's past comments, FDA's newly finalized psychedelic guidance, an active FDA-VA data-sharing arrangement, and a demonstrated agency willingness to fast-track sibling psychedelic drugs (Compass's psilocybin) — and even if this cycle fails, the long runway to 2030 leaves room for a second resubmission cycle to succeed. NOT FOUND: No confirmed FDA acceptance/filing decision on the August 2026 resubmission, no PDUFA date, and no statement from current FDA leadership (post-Makary, if changed) explicitly committing to a specific MDMA timeline or voucher award.

YES means: the FDA issues a formal approval letter (standard, accelerated, or REMS-restricted) for midomafetamine/MDMA for PTSD — i.e., Resilient Pharmaceuticals' NDA clears FDA review — at any point before January 1, 2030. - [2026-08-09] The current resubmission relies on a 32-person Phase I safety study plus a third-party audit of existing Phase 3 data rather than the new pivotal Phase 3 trial the FDA's 2024 Complete Response Letter explicitly demanded, meaning the core "dealbreaker" deficiencies — the agency's failure to collect 'positive' adverse events, insufficient durability data, and high rates of both prior MDMA use among participants and prescreening failures — may remain substantively unaddressed on re-review. - [2026-04/2026-09] Despite the White House's psychedelics executive order, MDMA/Resilient was passed over for a National Priority Voucher because, per legal analysis, MDMA has not yet received a voucher because it does not currently hold Breakthrough Therapy designation — the FDA declined to grant one to Lykos , a concrete structural reason the drug is on a slower track than its psychedelic peers (Compass, Usona, Transcend) even under the favorable political climate. - [2026-10 standing FDA rule] Under FDA's own Manual of Policies and Procedures, the FDA committed to user fee performance goals, including the goal of reviewing and acting on an applicant's resubmission of an original application in 6 months or less , and resubmissions are classified as Class 1 within 2 months of the receipt date… Class 2 within 6 months of the receipt date — but given the breadth and severity of the original CRL's efficacy, bias, and safety findings, industry resubmission guidance notes major clinical-data responses are classified Class 2, and if FDA disagrees with the sponsor's proposed Class 1 classification, it will reclassify to Class 2, which resets the PDUFA goal date to 6 months from the resubmission date — i.e., even a "fast" cycle likely runs to roughly February–March 2027 before any decision, with a further CRL fully plausible. - [2026-08-12] An analyst closely tracking the filing cautioned that the FDA's Division of Psychiatry (the actual reviewing unit) is presumably hoping that it has addressed FDA's dealbreakers, and it is now up to the age[ncy to decide] , while other sourcing in the same report flagged a possible middle path — a stringent REMS — rather than straightforward approval, and warned a more onerous REMS would have implications for scalability , underscoring that even a technical "approval" could come with restrictions that reflect continued unresolved agency skepticism rather than a clean resolution of the 2024 concerns. - [2026-09 third-party legal/industry tracker] An independent legal-status tracker's base-case projection states that industry analysts project a best-case rescheduling timeline of 2029 to 2030 for MDMA, built on the assumption the current resubmission path is viewed skeptically enough that full therapeutic legalization (approval plus rescheduling) may not land comfortably before the window closes. - [2024-06-04, still the operative precedent] The unusually lopsided adcomm vote — the FDA Psychopharmacologic Advisory Committee (PDAC) voted 2-9 against supporting the effectiveness of MDMA… and voted 1-10 to reject that the benefits of MDMA in combination with the FDA's proposed risk evaluation and mitigation strategy (REMS) outweigh its risks — remains unretracted and no new advisory committee has yet been convened to revisit this judgment on the resubmitted package, meaning the single clearest expert signal on record is still a near-unanimous rejection. - [2026-10-07, absence of evidence] As of the most recent trade-press recap, the MDMA NDA resubmission is listed only as a pipeline event for Q3 2026 with no acceptance letter, classification, or PDUFA date reported — consistent with status-quo inertia: nothing has yet started the regulatory clock that would need to run its course (plus likely at least one additional review cycle) before 2030. - [structural, deadline arithmetic] Even under a generous reading — FDA quickly deems the resubmission "complete," classifies it Class 2 (6-month clock), and does not issue a second CRL — a decision likely does not land before mid-2027; if instead FDA requires a major amendment (which may extend the PDUFA date by 3 months ) or issues a second CRL demanding further data (as the "two dealbreakers left unaddressed" framing above suggests is plausible), a third review cycle could easily push past 2028–2029, leaving limited but not zero buffer before the January 1, 2030 deadline. BOTTOM LINE: The strongest NO case rests on the combination of an unretracted 9-2/10-1 adcomm rejection, a resubmission that conspicuously skipped the specific new Phase 3 trial FDA demanded, MDMA's exclusion from the administration's own priority-voucher fast lane due to lacking Breakthrough Therapy designation, and the realistic prospect of at least one more multi-month Class 2 review cycle (or a second CRL) — all of which make continued non-approval through 2026-2028, and plausibly through 2029, a very defensible base case even with political tailwinds. NOT FOUND: No confirmation of FDA's formal acceptance/classification letter for the August 2026 resubmission, no PDUFA goal date, and no scheduled new Advisory Committee meeting as of October 7, 2026.